Normal view MARC view ISBD view

Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report.

MedStar author(s):

Citation: Cureus. 8(1):e457, 2016 Jan 12.PMID: 26918225Institution: MedStar Medical Group | Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Case ReportsSubject headings: PubMed-not-MEDLINE -- Not indexedYear: 2016 ISSN:

2168-8184

Name of journal: CureusAbstract: Gastroesophageal adenocarcinomas represent one of the top five most common types of cancer worldwide. Despite significant advancement, it is still not known which first-line chemotherapy option is best matched to an individual patient. The vast advances in molecular biology have led to the discovery of many potential predictive biomarkers, such as HER-2 neu, thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and topoisomerase-1 (TOPO1). These markers could allow us to select treatment based on an individual's tumor profile, resulting in an improvement of outcome. Our report highlights two patients with metastatic gastric cancer that achieved an exceptional response with traditional therapy and provides insights into the future perspectives of molecular profile-directed chemotherapy.All authors: Carroll JE, Colton B, Hartley M, Manning MA, Mikhail S, Salem ME, Smaglo BG, Xiu JFiscal year: FY2016Digital Object Identifier:

https://dx.doi.org/10.7759/cureus.457

Date added to catalog: 2019-03-14

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	26918225	Available		26918225

Gastroesophageal adenocarcinomas represent one of the top five most common types of cancer worldwide. Despite significant advancement, it is still not known which first-line chemotherapy option is best matched to an individual patient. The vast advances in molecular biology have led to the discovery of many potential predictive biomarkers, such as HER-2 neu, thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and topoisomerase-1 (TOPO1). These markers could allow us to select treatment based on an individual's tumor profile, resulting in an improvement of outcome. Our report highlights two patients with metastatic gastric cancer that achieved an exceptional response with traditional therapy and provides insights into the future perspectives of molecular profile-directed chemotherapy.

English